Through our advanced AI-based technology, Massive Bio breaks down barriers, connecting cancer patients worldwide with cancer clinical trials and offering support every step of the way.
We strive to create a world without cancer by empowering individuals everywhere with equal access to cancer clinical trials, utilizing concierge services, real-time data, and AI technology to bridge gaps in enhancing patient outcomes.
To be the world’s most powerful patient-centric oncology company, empowering patients to access the next generation of cancer discoveries under a single platform, leveraging technology to accelerate innovation, transform oncology, and save lives.
At Massive Bio, our core values stem from empowering patients in their cancer journey through innovative technology, driven by a passionate commitment to accessible and impactful care.
We are driven by an unwavering commitment to excellence and Massive Bio’s success.
We challenge assumptions and develop creative solutions to advance our mission.
We are results-oriented, demonstrating excellence and a bias for action.
We take proactive responsibility for our work and hold ourselves and others accountable.
We are eager learners who actively seek understanding and contribute effectively.
We’re dedicated to improving the lives of cancer patients through continuous innovation and collaborative partnerships. Our commitment is grounded in these five principles:
Our deep expertise in oncology and malignant hematology is reflected in our research published in multiple peer-reviewed journals.
According to your specific condition, we quickly connect you with trials that might be a good fit. We also keep track of your progress throughout the process.
We’re the only platform chosen by the National Cancer Institute (NCI) to work with their network of leading cancer centers. This gives you access to a wider range of trials.
We’re experts in helping patients find trials across the U.S., Canada, Latin America, and Europe.
We’re here to guide you through the process of joining a trial, making it as easy as possible.
Our worldwide recognition reflects our AI and data analytics capabilities in transforming oncology.
“Startup 100” List
Regional Winner in Artifical Intelligence
New York City Digital Health Top 100 List
Quarterfinalist for Artifical Intelligence Application
Co-Founder, CEO
Co-Founder, CMO
Co-Founder, CEO
In collaboration with the Precision Cancer Consortium (comprising JNJ, AstraZeneca, GSK, Bayer, Lilly, Novartis, and Roche), Massive Bio recently presented research at the American Society of Clinical Oncology (ASCO) annual meeting. The abstract, “Effect of a novel artificial intelligence (AI)-enabled multi-trial matching system on patient matching using real-world data,” demonstrates how Massive Bio’s AI-based platform significantly increases clinical trial matching rates and improves patient access to clinical trials.
